ELLA

This brand name is authorized in Canada, Hong Kong, Israel, Singapore, Turkey, United States

Active ingredients

The drug ELLA contains one active pharmaceutical ingredient (API):

1 Ulipristal UNII YF7V70N02B - ULIPRISTAL ACETATE

Ulipristal is an orally-active synthetic selective progesterone receptor modulator which acts via high-affinity binding to the human progesterone receptor. When used for emergency contraception the mechanism of action is inhibition or delay of ovulation via suppression of the luteinising hormone (LH) surge. Pharmacodynamic data show that even when taken immediately before ovulation is scheduled to occur (when LH has already started to rise), ulipristal acetate is able to postpone follicular rupture for at least 5 days. Read about Ulipristal

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ELLA Tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
G03AD02	Ulipristal	G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03A Hormonal contraceptives for systemic use → G03AD Emergency contraceptives
Discover more medicines within G03AD02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02436329
Country: HK	Department of Health Drug Office	Identifier(s): 61541, 63992
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 7813
Country: SG	Health Sciences Authority	Identifier(s): 13979P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699514094302
Country: US	FDA, National Drug Code	Identifier(s): 50102-911, 73302-456